People before percentages
Tailor Made Peptides Review begins with different bodies
A tailor needs the person in front of them. A peptide result needs its people too. A human MOTS-c study makes the easy story unravel.
94 people receiving dialysis
I hoped that human MOTS-c data would put firmer ground under the hopeful mouse results. Then came a study of 94 people receiving long-term hemodialysis, the machine-assisted blood cleaning needed when kidneys can no longer do enough of that work. Higher naturally circulating MOTS-c went with a greater risk of death or non-fatal cardiovascular events, counted together. Nobody in the study received MOTS-c treatment.
That result frustrates a tidy story about an energy-related peptide. It also leaves several explanations open: the blood level might reflect illness, a response to illness, or something the study could not separate. Giving additional MOTS-c would be a different experiment altogether.
For my money, this is where the interesting question begins. Which body, in which condition, is a claim supposed to fit? The dialysis finding gives the question some teeth. It supplies neither a reason to take MOTS-c nor proof that added MOTS-c would cause harm.
The measurement was of MOTS-c already in the blood. Treatment effects were never tested.
Allowance for difference
“Tailor made” sounds reassuring because it suggests someone has allowed for the awkward particulars. Published trials give us a more limited kind of fit: a defined group, a specified treatment and a set of outcomes. Even a well-run trial leaves room between its average and an individual life.
I distrust claims that erase that room. The semaglutide heart trial enrolled people who already had cardiovascular disease, excess weight and no diabetes. Its kidney trial concerned people with type 2 diabetes and chronic kidney disease. Both found benefit. The illnesses people brought into the trial help tell us where those findings apply.
That is the attraction of this collection for me: the same peptide name can appear in remarkably different company. The differences deserve more space than a footnote.
Two medicines in the same trial
There are comparisons that hold more of the setting steady. In the SURMOUNT-5 trial involving 751 adults with obesity and without type 2 diabetes, average weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide. That is a substantial advantage for the tirzepatide group under those trial conditions.
Head-to-head research earns a firmer place in my reckoning than a league table assembled from unrelated trials. It still leaves individual losses, tolerability and medical history to account for. The appeal of a single winning percentage is precisely how much it lets us forget.
A group mean describes the group. It cannot supply the missing measurements of a particular person.
The compound notes
Semaglutide moves between weight, heart and kidney trials; the people enrolled change with the question. Tirzepatide has direct comparisons worth taking seriously, alongside a less comfortable discussion about tolerability.
Retatrutide brings striking early results and the extra work of understanding a faster pulse. MOTS-c takes the longest journey, from cell compartments and mouse muscles to human blood measurements.
The comparison notes put those study populations together. The complete reading list includes the trials, laboratory papers and reviews.